Search Results

Ora, Inc. announced its participation as a major exhibitor in the Association for Research in Vision and Ophthalmology 2024 conference, and as host and convener of the Dry Horizons Symposium in partnership with Ophthalmology Innovation Source.

Ora, Inc., the foremost global ophthalmology contract research organization, announced a strategic, exclusive partnership with the Singapore Eye Research Institute, a world-renowned institution for cutting-edge eye research and ophthalmic preclinical studies.

OrthoPediatrics Corp. announced the Company has entered into an exclusive Distribution Agreement with Ora Medical, based in Montreal, to sell Ora Medical’s gait trainer, The Levity, a device designed for children with walking difficulties.

Ora, Inc. , the world’s leading Clinical Research Organization (CRO) for ophthalmology pharmaceutical and device development, announced today that Nate Speicher has been appointed Chief Financial Officer (CFO).

Ora, Inc. announced its partnership with the North West London Clinical Trials Alliance, a collaboration between clinical trial teams that aims to improve access to and the quality of clinical research in the region.

Oragenics, Inc. today announced that it has entered into a placement agency agreement for the purchase and sale of 1,100,000 shares of its common stock (or pre-funded warrants in lieu thereof) at an offering price of $1.00 per share.

Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced that it intends to offer and sell shares of its common stock.

Oragenics, Inc., a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, announced the closing of its public offering of 1,100,000 shares of its common stock at an offering price of $1.00 per share.

Oragenics, Inc. today announced that it received a notice (the “Notice”) from the NYSE American LLC (the “NYSE American”) dated June 18, 2024, notifying the Company that it has accepted the Company’s plan to regain compliance with NYSE American’s continued listing standards.

Oramed Pharmaceuticals Inc. announced today that its Board of Directors has authorized a common stock repurchase plan allowing for the buy-back of up to $20,000,000 in maximum value of its common stock through open market purchases, privately-negotiated transactions, or otherwise in compliance with Rule 10b-18 under the Securities Exchange Act of 1934, as amended, over the next 12 months.